p53 Immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer

A preliminary report of LCSG 871

D. P. Carbone, T. Mitsudomi, H. Chiba, S. Piantadosi, V. Rusch, J. A. Nowak, D. McIntire, D. Slamon, A. Gazdar, J. Minna

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

We investigated the correlation of p53 abnormalities with survival in 85 patients with non-small cell lung cancer (NSCLC) who had undergone resection with curative intent as part of Lung Cancer Study Group (LCSG) 871. Our previous studies showed that only a subset of p53 mutations in lung cancers result in overexpression. In addition, protein overexpression has been described in the absence of mutation. Therefore, we determined both p53 protein overexpression (by immunostaining) and p53 and ras gene mutations (by single-strand conformation polymorphism and DNA sequencing) in this set of resected tumor specimens. Clinical follow-up data were available for 75 cases. Of the studied patients, 64% showed p53 overexpression and 51% had mutant p53 sequences; however, the concordance rate was only 67%. There was a negative survival correlation with positive p53 immunostaining (p=0.05), but not with the presence of gene mutations (p=0.62) in this group of patients. Overexpression of p53 protein determined by immunostaining may contribute to adverse outcome due to the ability of p53 to act as a dominant oncogene, or alternatively, overexpression may reflect ongoing DNA damage in the tumor as a marker for a more aggressive behavior. When adjusted for stage, age, and gender by multivariate analysis, however, there was no independent impact of p53 overexpression on survival.

Original languageEnglish (US)
JournalChest
Volume106
Issue number6 SUPPL.
StatePublished - 1994

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Mutation
Survival
Genes
Proteins
ras Genes
p53 Genes
DNA Sequence Analysis
Oncogenes
DNA Damage
Neoplasms
Multivariate Analysis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

p53 Immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer : A preliminary report of LCSG 871. / Carbone, D. P.; Mitsudomi, T.; Chiba, H.; Piantadosi, S.; Rusch, V.; Nowak, J. A.; McIntire, D.; Slamon, D.; Gazdar, A.; Minna, J.

In: Chest, Vol. 106, No. 6 SUPPL., 1994.

Research output: Contribution to journalArticle

@article{38de469a437f40799d73ae24959ee0e1,
title = "p53 Immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer: A preliminary report of LCSG 871",
abstract = "We investigated the correlation of p53 abnormalities with survival in 85 patients with non-small cell lung cancer (NSCLC) who had undergone resection with curative intent as part of Lung Cancer Study Group (LCSG) 871. Our previous studies showed that only a subset of p53 mutations in lung cancers result in overexpression. In addition, protein overexpression has been described in the absence of mutation. Therefore, we determined both p53 protein overexpression (by immunostaining) and p53 and ras gene mutations (by single-strand conformation polymorphism and DNA sequencing) in this set of resected tumor specimens. Clinical follow-up data were available for 75 cases. Of the studied patients, 64{\%} showed p53 overexpression and 51{\%} had mutant p53 sequences; however, the concordance rate was only 67{\%}. There was a negative survival correlation with positive p53 immunostaining (p=0.05), but not with the presence of gene mutations (p=0.62) in this group of patients. Overexpression of p53 protein determined by immunostaining may contribute to adverse outcome due to the ability of p53 to act as a dominant oncogene, or alternatively, overexpression may reflect ongoing DNA damage in the tumor as a marker for a more aggressive behavior. When adjusted for stage, age, and gender by multivariate analysis, however, there was no independent impact of p53 overexpression on survival.",
author = "Carbone, {D. P.} and T. Mitsudomi and H. Chiba and S. Piantadosi and V. Rusch and Nowak, {J. A.} and D. McIntire and D. Slamon and A. Gazdar and J. Minna",
year = "1994",
language = "English (US)",
volume = "106",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6 SUPPL.",

}

TY - JOUR

T1 - p53 Immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer

T2 - A preliminary report of LCSG 871

AU - Carbone, D. P.

AU - Mitsudomi, T.

AU - Chiba, H.

AU - Piantadosi, S.

AU - Rusch, V.

AU - Nowak, J. A.

AU - McIntire, D.

AU - Slamon, D.

AU - Gazdar, A.

AU - Minna, J.

PY - 1994

Y1 - 1994

N2 - We investigated the correlation of p53 abnormalities with survival in 85 patients with non-small cell lung cancer (NSCLC) who had undergone resection with curative intent as part of Lung Cancer Study Group (LCSG) 871. Our previous studies showed that only a subset of p53 mutations in lung cancers result in overexpression. In addition, protein overexpression has been described in the absence of mutation. Therefore, we determined both p53 protein overexpression (by immunostaining) and p53 and ras gene mutations (by single-strand conformation polymorphism and DNA sequencing) in this set of resected tumor specimens. Clinical follow-up data were available for 75 cases. Of the studied patients, 64% showed p53 overexpression and 51% had mutant p53 sequences; however, the concordance rate was only 67%. There was a negative survival correlation with positive p53 immunostaining (p=0.05), but not with the presence of gene mutations (p=0.62) in this group of patients. Overexpression of p53 protein determined by immunostaining may contribute to adverse outcome due to the ability of p53 to act as a dominant oncogene, or alternatively, overexpression may reflect ongoing DNA damage in the tumor as a marker for a more aggressive behavior. When adjusted for stage, age, and gender by multivariate analysis, however, there was no independent impact of p53 overexpression on survival.

AB - We investigated the correlation of p53 abnormalities with survival in 85 patients with non-small cell lung cancer (NSCLC) who had undergone resection with curative intent as part of Lung Cancer Study Group (LCSG) 871. Our previous studies showed that only a subset of p53 mutations in lung cancers result in overexpression. In addition, protein overexpression has been described in the absence of mutation. Therefore, we determined both p53 protein overexpression (by immunostaining) and p53 and ras gene mutations (by single-strand conformation polymorphism and DNA sequencing) in this set of resected tumor specimens. Clinical follow-up data were available for 75 cases. Of the studied patients, 64% showed p53 overexpression and 51% had mutant p53 sequences; however, the concordance rate was only 67%. There was a negative survival correlation with positive p53 immunostaining (p=0.05), but not with the presence of gene mutations (p=0.62) in this group of patients. Overexpression of p53 protein determined by immunostaining may contribute to adverse outcome due to the ability of p53 to act as a dominant oncogene, or alternatively, overexpression may reflect ongoing DNA damage in the tumor as a marker for a more aggressive behavior. When adjusted for stage, age, and gender by multivariate analysis, however, there was no independent impact of p53 overexpression on survival.

UR - http://www.scopus.com/inward/record.url?scp=0028007561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028007561&partnerID=8YFLogxK

M3 - Article

VL - 106

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6 SUPPL.

ER -